Decreasing oxygen saturation with corresponding levels of NLR and D-dimer for understanding the interplay of inflammation. حسب Narendran Gopalan (110148)

Differences in mean number of papers (top) and co-authors (bottom) depending on (1) NI membership and (2) time joined NI. حسب William C. Barley (8915282)

الموضوعات:

Regression estimates and incidence rate ratios from GLMER for number of papers (top) and coauthors (bottom). حسب William C. Barley (8915282)

الموضوعات:

Image 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg حسب Ling Kui (6108440)

"…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"

Image 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg حسب Ling Kui (6108440)

"…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"

Image 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg حسب Ling Kui (6108440)

"…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"

Table 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.docx حسب Ling Kui (6108440)

"…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"

Table 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx حسب Ling Kui (6108440)

"…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"

Table 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx حسب Ling Kui (6108440)

"…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"

Image 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg حسب Ling Kui (6108440)

"…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"

Table 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx حسب Ling Kui (6108440)

"…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"

STORMS microbiome reporting checklist. حسب Katrine Carlsen (5477300)

الموضوعات:

Negative ion mode significant differential metabolites (Fold Change greater than 2 or less than 0.5). حسب Peng-fei Han (694841)

Positive ion mode significant differential metabolites (Fold Change greater than 2 or less than 0.5). حسب Peng-fei Han (694841)

Change in Watt’s Connectedness Scale, Subscales by Treatment Group. حسب Benjamin R. Lewis (22279166)

الموضوعات:

Primary and secondary efficacy end points (intention-to-treat population). حسب Benjamin R. Lewis (22279166)

الموضوعات:

Demographic and clinical characteristics of participants at baseline. حسب Benjamin R. Lewis (22279166)

الموضوعات:

Study-related adverse events. حسب Benjamin R. Lewis (22279166)

الموضوعات:

Study flow chart. حسب Benjamin R. Lewis (22279166)

الموضوعات:

Change in QIDS-SR-16 and MBI-HSS-MP by Treatment Group. حسب Benjamin R. Lewis (22279166)

الموضوعات: